Mandi L. Pratt-Chapman, PhD, on Oncology Care in the LGBTQI+ Community: Best Practices for Addressing Health Needs

NCCN 2023 Annual Conference


Mandi L. Pratt-Chapman, PhD, of the George Washington University Cancer Center, discusses the specific health-care needs for cancer screening, treatment, and survivorship among members of the LGBTQI+ community. Because clinical practices and research studies do not routinely collect sexual orientation and gender identity data, there is insufficient evidence to guide clinical care decision-making, Dr. Pratt-Chapman says.


Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Dr. Pratt-Chapman: Lesbian, gay, bisexual, transgender, queer, and intersex people have unique cancer considerations from risk to screening, to treatment, to survivorship. And this also applies to policy. So, local jurisdiction issues, insurance coverage issues. So, as a researcher, I'm a queer identifying researcher that focuses on the health and healthcare quality of LGBTQI people. And my research really kind of spans the range of sexual orientation and gender identity data collection and use, including how do we ask these questions? What response options do patients want? When are these data collected? How are these data used? For example, I am leading a study that is looking at the wording of these questions as well as response options. I also led the development of cultural and clinical competency training for multidisciplinary teams to look at the range of unique issues for queer populations. Again, spanning from risk reduction through survivorship. And really, queer rights are human rights. And so as an advocate, I'm really encouraging clinicians and administrators to do what they can, where they are, where they live and work to make sure that patients are safe in disclosing their sexual orientation gender identity, that they support the appropriate collection of these data and use in clinical practice and research, that clinical trials are inclusive, that clinical settings are affirming, and that we're able to better gather data to guide clinical care decisions in the future. I recently wrapped up a study where I was collecting data from radiologists and radiation oncologists, and what was really clear was that transgender and intersex people in particular are facing clinical interactions and clinical care environments where at minimum they may be erased or invisible. And in many instances, providers don't feel clinically prepared or confident to care for the needs of these populations. And the vast majority of providers really want to provide good care. But there's a lack of systematic education and training for providers in kind of the differences in terms of, for example, anatomy that may or may not be present, or protections for individuals that may be seeking gender-affirming surgery at a later date and what that might mean for radiation treatment. And so just accounting for the values and preferences of care of patients across the care continuum and attending to anatomy as opposed to sex and gender markers. Considering endogenous and exogenous hormones when you're thinking about medical management and really trying to degender clinical settings so that they're inclusive and comfortable for all populations are some of the ways that providers can help to move the needle and provide more affirming care to these populations. NCCN and ASCO are committed to degendering guidelines. Coming soon, also are changes to HEDIS measures. So, there will be more anatomy driven cancer screening outcome measures in the future. So, administrators and clinicians can get ahead of this really by focusing on anatomy appropriate cancer screening as opposed to gendered cancer screening, and thinking about the whole person, the anatomy, the hormones, and the identity of people rather than kind of the binary sex markers that we've typically used in healthcare practice.

Related Videos

Natalie Moryl, MD, on Managing Pain in Patients With Cancer

Natalie Moryl, MD, of Memorial Sloan Kettering Cancer Center, discusses severe cancer pain, a medical emergency that should be addressed with immediate intervention. The treatment plan, Dr. Moryl says, should include making a pain diagnosis; addressing reversible causes of pain such as spinal cord compression, fracture, or obstruction; selecting, titrating, and rotating opioids and co-analgesics; and routine screening for risks of opioid use disorder and mental health comorbidities.

Elena Ratner, MD, MBA on Sexual Identity and Function in Cancer Survivors

Elena Ratner, MD, MBA, of Yale Cancer Center/Smilow Cancer Hospital, discusses sexuality, intimacy, fertility, and menopause as important aspects of women’s cancer survivorship and the many effects of treatment on these issues. They often go unacknowledged in the medical community, Dr. Ratner says, because of a lack of knowledge and resources. She describes interventions, including holistic, hormonal, behavioral, psychological, and interdisciplinary approaches.

Gastroesophageal Cancer

Michael K. Gibson, MD, PhD, on Metastatic Esophageal Squamous Cell Carcinoma: New First-Line Systemic Treatment Options

Michael K. Gibson, MD, PhD, of Vanderbilt-Ingram Cancer Center, discusses the importance of developing additional treatment strategies for patients with advanced or metastatic esophageal squamous cell carcinoma and describes the role of immune checkpoint inhibitors. Dr. Gibson also reviews the available evidence on the use of nivolumab in this patient population.

Solid Tumors

Mitesh J. Borad, MD, on Hepatobiliary Cancers: Management Updates

Mitesh J. Borad, MD, of the Mayo Clinic Comprehensive Cancer Center, discusses the expanding number of options in immunotherapies for patients with advanced hepatobiliary cancers, applying targeted treatments to this disease, and the importance of genomic profiling in patients with biliary tract cancers.


Jordan McPherson, PharmD, MS, BCOP, on Managing Immunotherapy-Related Toxicities

Jordan McPherson, PharmD, MS, BCOP, of the Huntsman Cancer Institute at the University of Utah, summarizes a case-based panel discussion on best practices in caring for patients with immune-related adverse events. He focuses on pneumonitis, which can occur with immune checkpoint inhibitor therapy, detailing factors such as comorbidities, infectious etiology, and disease progression; the need to consider myositis and myasthenia gravis in patients who develop immune-related myocarditis; and oral toxicities including mucositis and sicca syndrome.